CA
KROS icon

Cliff Asness’s Keros Therapeutics KROS Stock Holding History

Cliff Asness’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
967,859
+561,296
+138% +$6.25M ﹤0.01% 1557
2026
Q1 		$4.49M Buy
406,563
+226,020
+125% +$3.49M ﹤0.01% 1820
2025
Q4 		$3.68M Sell
180,543
-23,808
-12% -$418K ﹤0.01% 1764
2025
Q3 		$3.23M Buy
204,351
+133,701
+189% +$1.98M ﹤0.01% 1698
2025
Q2 		$943K Buy
70,650
+48,514
+219% +$655K ﹤0.01% 2239
2025
Q1 		$226K Buy
+22,136
New +$257K ﹤0.01% 2824
2023
Q3 		– Sell
-11,441
Closed -$460K – 2344
2023
Q2 		$460K Buy
11,441
+3,850
+51% +$169K ﹤0.01% 1813
2023
Q1 		$324K Buy
+7,591
New +$383K ﹤0.01% 1924

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Cliff Asness's KROS Position: Q2 2026 in Review

Cliff Asness increased its Keros Therapeutics (KROS) stake by 138% in Q2 2026, buying an estimated $6.25M and bringing the position to 967,859 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1557.

Cliff Asness first reported a position in KROS in Q1 2023 and has held it in 8 quarters since. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Cliff Asness held 967,859 shares of Keros Therapeutics worth $10.4M as of Q2 2026.
  • Cliff Asness bought 561,296 Keros Therapeutics shares in Q2 2026, an estimated $6.25M.
  • Keros Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1557 holding.
  • Cliff Asness first reported a position in Keros Therapeutics in Q1 2023 and has held it in 8 quarters since.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.